Skip to main content
. 2020 Jun 20;2020:9243681. doi: 10.1155/2020/9243681

Figure 3.

Figure 3

Combination of SMI and cisplatin suppresses A549/DDP cell glycolysis and proliferation and promotes apoptosis. (a) Glucose consumption and (b) lactate production were measured with SMI at concentrations of IC5, IC10, and IC20 combined with cisplatin (IC20) in cisplatin-resistant A549/DDP cells. (c) Expression levels of glycometabolic key enzymes were measured with SMI at concentrations of IC5, IC10, and IC20 combined with cisplatin (IC20) in cisplatin-resistant A549/DDP cells by western blot analysis. (d) Edu assay analyzed the proliferation of cisplatin-resistant A549/DDP cells with SMI at concentrations of IC5, IC10, and IC20 combined with cisplatin (IC20) for 24 h. (e) Western blot measured the expression of apoptosis-related proteins of cisplatin-resistant A549/DDP cells with SMI at concentrations of IC5, IC10, and IC20 combined with cisplatin (IC20) for 24 h. (f) The effects of SMI at concentrations of IC5, IC10, and IC20 combined with cisplatin (IC20) on the growth of cisplatin-resistant A549/DDP cells were measured at 1, 2, 3, 4, and 5 days, respectively. The results are expressed as the mean ± S.D. (n = 3); the experimental results are presented in triplicate. NC: negative control; SMI: Shenmai injection.